Theranautilus Secures $1.2 Mn in Seed...
19 Nov 2024
Emcure Pharmaceuticals has secured approval from the Securities and Exchange Board of India (SEBI) for its upcoming initial public offering (IPO), anticipated to launch within the next two months.
The IPO will include a fresh equity sale valued at ₹800 crore and an offer for sale (OFS) of 1.36 crore equity shares from promoters and existing shareholders. Among those selling shares in the OFS are promoter Satish Mehta and BC Investments IV Limited, an affiliate of Bain Capital, a US-based private equity firm.
Emcure Pharmaceuticals plans to allocate the net proceeds from the IPO towards debt repayment and general corporate purposes.
Based in Pune and backed by Bain Capital, Emcure Pharmaceuticals develops, manufactures, and markets a diverse range of pharmaceutical products worldwide, covering multiple major therapeutic areas.
The IPO will be managed by Kotak Mahindra Capital Company, Jefferies India, Axis Capital, and JP Morgan India as the book-running lead managers.
Chat on WhatsApp
Request a call back
